Bremelanotide

Overview

Bremelanotide (Vyleesi) is one of only two FDA-approved pharmacologic treatments for HSDD in women — the other being flibanserin (Addyi). It received approval in June 2019 based on robust Phase III data from the RECONNECT trial program. Its mechanism is centrally mediated, acting on melanocortin-4 receptors in the brain to modulate sexual desire and motivation rather than working through hormonal or vascular pathways. This makes it distinct from treatments that address sexual dysfunction through testosterone supplementation or PDE5 inhibition.

Bremelanotide vs. PT-141

Bremelanotide and PT-141 refer to the same core compound. PT-141 is the name used in earlier research and is the version circulated in compounding pharmacy and research peptide contexts. Vyleesi is the approved pharmaceutical product. The clinical pharmacology is the same; the distinction is regulatory and formulation-based. PT-141 in research settings is often used off-label in men for erectile dysfunction and in women outside the approved population — neither use has FDA approval.

Evidence Summary

The evidence base for bremelanotide’s approved indication is strong. The Phase III trials were adequately powered, well-designed, and showed consistent results across both co-primary endpoints (change in satisfying sexual events and change in distress). The nausea rate (40%) is a real clinical limitation and the primary reason many patients discontinue. The blood pressure effect, while generally transient, warrants caution in patients with baseline cardiovascular risk.

Regulatory Status

FDA-approved (NDA 210557) for acquired, generalized HSDD in premenopausal women. Prescription only. Available as Vyleesi auto-injector. Not approved for men, postmenopausal women, or any other indication. Off-label use exists but is not endorsed by labeling.